Bayer Investor News | Bayer Global

Stay informed about key developments at our company as they happen. Discover our Ad-Hoc Releases and subscribe to our newsletter to receive the latest news and topics of interest.

1 - 10of 452 News

1 - 10of 452 News

December 22, 2025

Not intended for U.S. and UK Media

Finerenone approved in Japan for treatment of patients with chronic heart failure

December 12, 2025

Not intended for U.S. and UK Media

Aflibercept 8 mg recommended for EU approval for third retinal indication

December 01, 2025

Bayer welcomes Solicitor General support for U.S. Supreme Court review

November 23, 2025

Bayer’s FXIa inhibitor Met Primary Efficacy and Safety Endpoints in Landmark Phase III Study in Secondary Stroke Prevention

November 20, 2025

Not intended for U.S. and UK Media

Accelerated approval in the U.S. for new treatment for patients with previously treated advanced HER2-mutant non-small cell lung cancer

November 19, 2025

EU approval for new hormone-free treatment option for vasomotor symptoms associated with menopause or caused by endocrine therapy for breast cancer

November 12, 2025

Business figures for the third quarter:

Bayer confirms 2025 Group outlook, progresses on strategic priorities

November 06, 2025

Dr. Judith Hartmann to become new Chief Financial Officer of Bayer AG

November 06, 2025

Not intended for U.S. and UK Media – Late-Breaking data from FINE-ONE Phase III study presented at ASN Kidney Week 2025

Bayer's Non-Steroidal MRA showed statistically significant reduction of UACR in adults with chronic kidney disease associated with type 1 diabetes

October 30, 2025

PCB litigation: Washington Supreme Court ruling in Erickson

Inform Yourself on Special Topics

Control Weeds Not Farming

Control Weeds, Not Farming

Farmers discussing their weed management

Everything You Need to Know About Glyphosate

some-bayer-group-headquarters

Managing Glyphosate Litigation

woman harvesting carrots

Managing and Mitigating PCB Litigation Risk